Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions

Bruton’s Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic. However, ibrutinib’s feasibil...

Descripción completa

Detalles Bibliográficos
Autores principales: Szklener, Katarzyna, Michalski, Adam, Żak, Klaudia, Piwoński, Michał, Mańdziuk, Sławomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032968/
https://www.ncbi.nlm.nih.gov/pubmed/35456016
http://dx.doi.org/10.3390/cells11081338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032968/
https://www.ncbi.nlm.nih.gov/pubmed/35456016
http://dx.doi.org/10.3390/cells11081338

Ejemplares similares